ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)

Contributed by: Business Wire

Logo

Business Wire logo

Images

Portrait: Dr. Rudolf Widmann | Member of the Board of Directors & Founder | AOP Health | Photocredit: AOP Health | Ospelt Photography
Portrait: Dr. Rudolf Widmann | Member of the Board of Directors & Founder | AOP Health | Photocredit: AOP Health | Ospelt Photography
Business Wire embedded0

Tags

Research
Legal
Clinical Trials
Professional Services
Biotechnology
General Health
Pharmaceutical
Health
Science
Other Science
BESREMi®

More Like This

Professor Jean-Jacques Kiladjian, University of Paris, France Photo credit: AOP Health/Lorenz Paulus

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results

Professor Heinz Gisslinger, MedUni Vienna/Austria (Fotocredit: IntMedCom)

Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera to Be Presented at the American Society of Hematology (ASH) 65th Annual Meeting

AOP Health CEO Martin Steinhart (Copyright: AOP Health/Studio Koekart)

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells

Group photo management AOP Health and RHEACELL, from left to right: Dr. Christoph Ganss, Dr. Andreas Kluth, RHEACELL Dr. Rudolph Widmann, Dr. Günther Krumpl, Dr. Martin Steinhart, Bernhard Nachbaur, LL.M., AOP Health

RHEACELL and AOP Health: Strategic Partnership to Deliver Breakthrough Therapies for the “Butterfly Children’s Disease” and Chronic Venous Wounds

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

PR Newswire associated0

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

PR Newswire associated0

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

Portrait of Dr. Martin Steinhart, CEO AOP Health (Photo: AOP Health/Studio Koekart)

U.S. FDA Approves AOP Health’s RapiblykTM (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting